AR117404A2 - Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación - Google Patents

Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación

Info

Publication number
AR117404A2
AR117404A2 ARP190100714A ARP190100714A AR117404A2 AR 117404 A2 AR117404 A2 AR 117404A2 AR P190100714 A ARP190100714 A AR P190100714A AR P190100714 A ARP190100714 A AR P190100714A AR 117404 A2 AR117404 A2 AR 117404A2
Authority
AR
Argentina
Prior art keywords
dosage unit
constipation
treatment
unit including
prostaglandin
Prior art date
Application number
ARP190100714A
Other languages
English (en)
Inventor
Myra L Patchen
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23293447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR117404(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of AR117404A2 publication Critical patent/AR117404A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/23—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)

Abstract

Reivindicación 1: Una unidad de dosificación formulada como una cápsula blanda de gelatina, caracterizada porque comprende un relleno líquido comprendiendo un análogo de prostaglandina y un triglicérido de ácido graso de cadena mediana, donde el análogo de prostaglandina es 13,14-dihidro-15-ceto-16,16-difluoro prostaglandina E1 y el análogo de prostaglandina está presente en un rango de aproximadamente 6 - 96 mg.
ARP190100714A 2001-11-14 2019-03-21 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación AR117404A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33131601P 2001-11-14 2001-11-14

Publications (1)

Publication Number Publication Date
AR117404A2 true AR117404A2 (es) 2021-08-04

Family

ID=23293447

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP020104349A AR037524A1 (es) 2001-11-14 2002-11-13 Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
ARP140104956A AR098997A2 (es) 2001-11-14 2014-12-30 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación
ARP190100714A AR117404A2 (es) 2001-11-14 2019-03-21 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP020104349A AR037524A1 (es) 2001-11-14 2002-11-13 Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
ARP140104956A AR098997A2 (es) 2001-11-14 2014-12-30 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación

Country Status (14)

Country Link
US (3) US8097653B2 (es)
EP (2) EP1443938B1 (es)
JP (2) JP4852229B2 (es)
AR (3) AR037524A1 (es)
AT (1) ATE522218T1 (es)
BR (1) BR0214075A (es)
CA (1) CA2464420C (es)
CY (1) CY1115856T1 (es)
DK (2) DK1443938T3 (es)
ES (2) ES2368729T3 (es)
LU (1) LU92826I2 (es)
PT (2) PT2298314E (es)
TW (1) TWI331920B (es)
WO (1) WO2003041716A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331920B (en) * 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
EP1562604B1 (en) * 2002-10-23 2012-01-04 Sucampo AG Prostaglandin compounds for the treatment of obesity
AU2003292556B2 (en) * 2002-12-27 2009-09-10 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
US8337891B2 (en) * 2003-07-03 2012-12-25 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) * 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
EP1871380B1 (en) * 2005-04-12 2011-10-19 Sucampo AG Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
CA2637275C (en) 2006-01-24 2014-12-09 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
RU2420291C3 (ru) * 2006-01-24 2020-07-21 Р-Тек Уено, Лтд. Состав в мягкой желатиновой капсуле
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
JP5797655B2 (ja) * 2009-09-18 2015-10-21 アドラー・コーポレーション 消化管障害のためのオピオイド受容体アンタゴニストの使用
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5350141A (en) 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
GB1581886A (en) 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
ATE78465T1 (de) * 1987-10-02 1992-08-15 Ueno Seiyaku Oyo Kenkyujo Kk Kathartica.
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CA2030346C (en) 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
CA2046069C (en) 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
JP2938579B2 (ja) * 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
PH31171A (en) * 1992-02-04 1998-03-20 Esai Co Ltd Aminobenzonic acid derivatives useful for treatinggastrointestinal conditions.
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
US6242485B1 (en) * 1996-06-10 2001-06-05 R-Tech Ueno Endothelin antagonist
DE19717005A1 (de) * 1997-04-23 1998-10-29 Kennametal Inc Spannfutter für Rundlaufwerkzeuge
EP0978284B1 (en) 1997-11-28 2008-07-23 Sucampo AG Use of 15-keto-prostaglandin-e compounds as endothelin antagonists
US6492417B1 (en) 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
DE60039727D1 (de) * 1999-10-15 2008-09-11 Sucampo Ag Neue Zusammensetzung enthaltend eine bicyclische Verbindung und ein Glycerid
JP4183943B2 (ja) 2000-04-06 2008-11-19 スキャンポ・アーゲー １５−ケトプロスタグランジンを含む胆汁分泌促進剤組成物
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
AR035242A1 (es) 2001-05-18 2004-05-05 Sucampo Ag Uso de un lipido bioactivo halogenadopara preparar una composicion catartica y compuesto lipido bioactivo halogenado
AU2002330747B2 (en) 2001-08-31 2007-07-19 Sucampo Ag Prostaglandin analogs as chloride channel opener
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
AU2003292556B2 (en) 2002-12-27 2009-09-10 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort

Also Published As

Publication number Publication date
JP4852229B2 (ja) 2012-01-11
JP2011201905A (ja) 2011-10-13
DK1443938T3 (da) 2011-09-26
TW200300091A (en) 2003-05-16
US20130143958A1 (en) 2013-06-06
EP1443938A1 (en) 2004-08-11
AR037524A1 (es) 2004-11-17
JP2005513014A (ja) 2005-05-12
WO2003041716A1 (en) 2003-05-22
LU92826I2 (fr) 2015-11-24
BR0214075A (pt) 2004-09-28
PT1443938E (pt) 2011-09-27
ATE522218T1 (de) 2011-09-15
US8097653B2 (en) 2012-01-17
US20120088824A1 (en) 2012-04-12
CY1115856T1 (el) 2017-01-25
ES2524369T3 (es) 2014-12-05
EP1443938B1 (en) 2011-08-31
EP2298314B1 (en) 2014-09-03
CA2464420A1 (en) 2003-05-22
HK1155649A1 (en) 2012-05-25
US20030119898A1 (en) 2003-06-26
DK2298314T3 (en) 2014-12-01
CA2464420C (en) 2011-12-13
US8389542B2 (en) 2013-03-05
PT2298314E (pt) 2014-12-03
AR098997A2 (es) 2016-06-22
TWI331920B (en) 2010-10-21
EP2298314A1 (en) 2011-03-23
ES2368729T3 (es) 2011-11-21

Similar Documents

Publication Publication Date Title
ES2174814T3 (es) Acidos grasos esenciales destinados en la prevencion de accidentes cardio-vasculares.
ES2195798T1 (es) Formulacion para mujeres menopausicas.
ES2392590T3 (es) Formulación de cápsula de gelatina blanda
ATE207346T1 (de) Orale pharmazeutische zusammensetzungen mit sexualhormonen
EE200200718A (et) Rasvhapete terapeutilised kombinatsioonid
AR025599A1 (es) Metodo para mejorar la piel y el pelaje de mascotas
EP1537069A4 (en) ANALOGUE OF OMEGA-3 PUFA DERIVED LIPID MEDIATORS AND METHOD OF USE
ES2136100T3 (es) Composicion lipida para productos cosmeticos que contienen trigliceridos de acidos grasos insaturados.
ES2195175T3 (es) Preparacion farmaceutica que comprende acido eicosapentaenoico y/o acido estearidonico.
BRPI0009373B8 (pt) composições farmacêuticas orais contendo triglicerídeos de cadeia longa e tensoativos lipofílicos
ES2068800T1 (es) Preparacion farmaceutica en forma de un comprimido efervescente o de desintegracion o un granulado soluble al instante, y procedimiento para su produccion.
AR029615A1 (es) Una formulacion farmaceutica para la administracion oral
CO5611100A2 (es) Preparacion farmaceutica que contiene oxicodona y naloxona
MX9701417A (es) Formulaciones de actividad superficial.
AR098997A2 (es) Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación
EP1698685A4 (en) FAT COMPOSITION
ES2188433T1 (es) Procedimiento para la preparacion de sales calcicas de acidos grasos para gliceridos elevados en contenidos de aceites.
CO5160323A1 (es) Formulaciones farmaceuticas mejoradas vir en combinacion con otros inhibidores de proteasa vih
ES2149253T3 (es) Medicamentos a base de acido docosahexaenoico como antiagregantes plaquetarios y contra las carencias cerebrales en acidos grasos esenciales y procedimientos de preparacion.
PE20220506A1 (es) Composicion de recubrimiento comestible para recubrir productos frescos cosechados
UY28586A1 (es) Formas de administración masticables, no comprimidas dosificadas individualmente
BRPI0418070A (pt) composição para cuidados pessoais, uso de uma uréia substituìda e método para reduzir a degradação da cor de uma composição para cuidados pessoais
ES2531599T3 (es) Utilización de triglicéridos docosahexaenoicos para el tratamiento de enfermedades tumorales
CO4780020A1 (es) Formulaciones farmaceuticas de liberacion prolongada, que contienen mizolastina
SE9704590D0 (sv) Method of increasing the production and improving the quality of semen

Legal Events

Date Code Title Description
FC Refusal